Carl L. G. Hansen is CEO at AbCellera Biologics Inc. (ABCL). They have made 1 open-market trade across 1 company since 2021, most recently 2024-11-25.
CIK 0001834412
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABCL | 898,000 | $11.1M |
Shares reported on the most recent Form 4, priced at the 2024-11-26 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABCL | SELL | 2021-06-09 | 2021-06-10 | $24.08 | $279.3M | -13.3% | -26.8% | -28.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.